Phase I/Ib Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (DOSE SELECTION)
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2018
At a glance
- Drugs Guadecitabine (Primary) ; Mocetinostat (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DOSE SELECTION
- 18 Oct 2018 Planned number of patients changed from 57 to 40.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.
- 21 Jul 2017 New trial record